Kynurenine and uric acid levels in chronic myeloid leukemia patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294984" target="_blank" >RIV/00216208:11110/15:10294984 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/15:10294984 RIV/00179906:_____/15:10294984 RIV/00064165:_____/15:10294984

Výsledek na webu

<a href="http://www.tandfonline.com/doi/full/10.4161/2162402X.2014.992646" target="_blank" >http://www.tandfonline.com/doi/full/10.4161/2162402X.2014.992646</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4161/2162402X.2014.992646" target="_blank" >10.4161/2162402X.2014.992646</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Kynurenine and uric acid levels in chronic myeloid leukemia patients

Popis výsledku v původním jazyce

Indoleamine 2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan 2,3-dioxygenase (TDO) represent some of the key immune regulators. Their increased activity has been demonstrated in a number of human malignancies but not yet in chronic myeloid leukemia (CML). In the present study, the activity of these enzymes was tested in 29 CML patients and 28 healthy subjects by monitoring the kynurenine (KYN)/tryptophan ratio. Serum samples taken prior to the therapy displayed a highly significant difference in KYN levelsbetween the patient and control groups. However, increased KYN levels were detected in only 13 (44.8%) of these CML patients. The KYN levels in pretreatment sera of the patients correlated with the tumor burden. There was also a strong correlation between KYN levels and uric acid levels (UA). This suggests but does not prove the possible involvement of UA in activating IDO family of enzymes. Whenever tested, the increased KYN levels normalized in the course of the therapy. Patients with

Název v anglickém jazyce

Kynurenine and uric acid levels in chronic myeloid leukemia patients

Popis výsledku anglicky

Indoleamine 2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan 2,3-dioxygenase (TDO) represent some of the key immune regulators. Their increased activity has been demonstrated in a number of human malignancies but not yet in chronic myeloid leukemia (CML). In the present study, the activity of these enzymes was tested in 29 CML patients and 28 healthy subjects by monitoring the kynurenine (KYN)/tryptophan ratio. Serum samples taken prior to the therapy displayed a highly significant difference in KYN levelsbetween the patient and control groups. However, increased KYN levels were detected in only 13 (44.8%) of these CML patients. The KYN levels in pretreatment sera of the patients correlated with the tumor burden. There was also a strong correlation between KYN levels and uric acid levels (UA). This suggests but does not prove the possible involvement of UA in activating IDO family of enzymes. Whenever tested, the increased KYN levels normalized in the course of the therapy. Patients with

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12363" target="_blank" >NT12363: Prohloubení znalostí o imunologie chronické myeloidní leukemie: předpoklad vývoje terapeutické vakcíny</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OncoImmunology

ISSN

2162-402X

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

000352612900027

EID výsledku v databázi Scopus

2-s2.0-84924310773